Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13203983 | 0.84 | NOTUM (0.53) | NOTUMSIGMAR1EBPSLC18A3HDAC1 | |
| SCHEMBL13203954 | 0.79 | SIGMAR1 (0.58) | NOTUMSIGMAR1 | |
| SCHEMBL2982201 | 0.77 | NOTUM (0.62) | NOTUMHSD11B1 | |
| SCHEMBL13203950 | 0.76 | KDM4E (0.47) | NOTUM | |
| SCHEMBL1713006 | 0.75 | CYP2D6 (0.56) | NOTUMSIGMAR1HDAC1HDAC8HDAC6 | |
| SCHEMBL13203987 | 0.75 | NOTUM (0.42) | NOTUMSIGMAR1EBPSLC18A3HDAC1 | |
| SCHEMBL2758088 | 0.74 | SIGMAR1 (0.70) | SIGMAR1EBP | |
| SCHEMBL13203957 | 0.74 | NOTUM (0.43) | NOTUMSIGMAR1EBPSLC18A3HDAC1 | |
| SCHEMBL2971570 | 0.73 | NOTUM (0.53) | NOTUMHDAC1HDAC8HDAC6HSD11B1 | |
| SCHEMBL2758157 | 0.72 | MCHR2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| WO-2008021545-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063021-A9 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | NOTUM 1391/4885SIGMAR1 237/4885EBP 2877/4885 |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | HRH2, ACHE, CHRM2 | NOTUM 3021/4885SIGMAR1 197/4885EBP 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.